Clinical Study of Anti-CD19/BCMA Bispecific Chimeric Antigen Receptors (CARs) T Cell Therapy for Relapsed and Refractory Multiple Myeloma
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Anti CD19 anti BCMA bispecific chimeric antigen receptor T cell therapy Hrain Biotechnology (Primary) ; Cyclophosphamide; Fludarabine
- Indications Multiple myeloma
- Focus Adverse reactions
- 25 Oct 2018 New trial record